Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) shares decreased -1.08% in last trading session and ended the day at $1.83. WHLR Gross Margin is 73.10% and its has a return on assets of -36.10%. Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) quarterly performance is -4.69%.
Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) announced that its Board of Directors has authorized a $0.0175 per share monthly cash dividend for shareholders of record of the Company’s common stock on November 30, 2015, to be paid on or about December 31, 2015.
Facebook Inc (NASDAQ:FB) shares decreased -0.31% in last trading session and ended the day at $105.41. FB Gross Margin is 83.10% and its has a return on assets of 6.50%. Facebook Inc (NASDAQ:FB) quarterly performance is 17.47%.
On 20 November, Facebook Inc (NASDAQ:FB) revealed that it was developing a work-focused version of its social networking tools to try and convert its consumer success into a new stream of revenue from businesses.
Alphabet Inc (NASDAQ:GOOG) caters to the Technology space. Its weekly performance is 1.10%. On the last day of trading company shares ended up at $748.15. Alphabet Inc (NASDAQ:GOOG) distance from 50-day simple moving average (SMA50) is 57.21%.
On 20 November, Alphabet Inc (NASDAQ:GOOG) said that, it is serious about taking over the cloud from its much bigger rivals, and this is clear in the words of Larry Page, Google’s co-founder. He called Ms. Green’s new post a “huge new responsibility at Google” in line with the words of Urs that Google wants to become a “cloud company by 2020.
Dynavax Technologies Corporation (NASDAQ:DVAX) shares advanced 4.14% in last trading session and ended the day at $26.40. DVAX has a return on assets of -68.30%. Dynavax Technologies Corporation (NASDAQ:DVAX) quarterly performance is -7.21%.
Dynavax Technologies Corporation (NASDAQ:DVAX) was upgraded by Zacks from a “hold” rating to a “buy” rating in a report released on Thursday, Market Beat reports. The firm presently has a $25.00 price objective on the biopharmaceutical company’s stock. Zacks‘s price target would suggest a potential upside of 13.22% from the company’s current price.
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) caters to the Healthcare space. Its weekly performance is 15.17%. On the last day of trading company shares ended up at $8.20. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) distance from 50-day simple moving average (SMA50) is -4.13%.
On 19 November, Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced a collaboration to explore the potential utility of daily physiological activity monitoring in boys affected by Duchenne muscular dystrophy (DMD) with ActiGraph, a leading provider of objective physical activity and sleep/wake measurement solutions for the global scientific community. Catabasis is launching a new observational trial to measure the daily physical activity of patients affected by Duchenne.
Leave a Reply